CD19 and acute lymphoblastic leukemia: One of these studies, a phase I trial of CD19-CAR T cells used in refractory B-cell malignancies, reported a CR in 70% of patients with acute lymphoblastic leukemia (B-ALL) as well as an OS at a median followup of 10 months with 51.6% at 9.7 months (197).